Sustained Maternal Antibodies Against Parechovirus‐A3 During the Coronavirus Disease 2019 Pandemic
Journal of Medical Virology · 2025
DOI: 10.1002/jmv.70313 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medical Virology, 2025. Verfasst von Jun Tachikawa und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Graduate School of Medical and Dental Sciences, Niigata University, Niigata, Japan. Hauptthemen laut MEDLINE: Antibodies, Viral, Parechovirus, Antibodies, Neutralizing, COVID-19. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 20 Literaturangaben. Gefördert von: This work was supported by the Japan Society for the Promotion of Science KAKENHI (grant number 23K14969 to YA, 21KK0166 to AS)..
Abstract (Originalsprache)
The epidemiology of parechovirus‐A3 (PeV‐A3) infection in neonates and young infants changed during the coronavirus disease 2019 (COVID‐19) pandemic. We hypothesized the pandemic impacted maternal antibodies against PeV‐A3. To test this hypothesis, we measured neutralizing antibody titers (NATs) against PeV‐A3 in 102 cord blood samples from full‐term infants born in June–December 2023 at Niigata University Hospital in Niigata, Japan. Maternal data were collected and compared the findings with our previous pre‐pandemic data. The median maternal age was 34.5 years (range: 30–37 years). The geometric mean titer (GMT) against PeV‐A3 was 98.4 (95% confidence interval [CI]: 61.7–156.8). The GMT for ages 25–34 years (184.6, n = 45) and 35–44 years (56.3, n = 51) sustained at the same level when we compared to age‐matched pre‐pandemic data for ages 16–24 years (336.5, n = 11, p = 0.84) and 25–34 years (31.9, n = 107, p = 0.14), respectively. By multivariable logistic regression analyses, maternal age ≤ 34 years was associated with higher seropositivity (adjusted odds ratio [aOR] 3.12, 95% CI 1.18–8.78, p = 0.03). Maternal NATs against PeV‐A3 were sustained at the same level during the COVID‐19 pandemic, indicating intra‐pandemic maintenance of humoral immunity to PeV‐A3 in women of childbearing age.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pediatrics, Graduate School of Medical and Dental Sciences, Niigata University, Niigata, Japan.
- Department of Medical Technology, Graduate School of Health Sciences, Niigata University, Niigata, Japan.
- Department of Obstetrics and Gynecology, Graduate School of Medical and Dental Sciences, Niigata University, Niigata, Japan.
ORCID-Profile: Jun Tachikawa, Yuta Aizawa, Akihiko Saitoh
Förderung
- This work was supported by the Japan Society for the Promotion of Science KAKENHI (grant number 23K14969 to YA, 21KK0166 to AS).
Zitieren
APA
Tachikawa, J., Aizawa, Y., Watanabe, K., Haino, K., Nishijima, K., & Saitoh, A. (2025). Sustained Maternal Antibodies Against Parechovirus‐A3 During the Coronavirus Disease 2019 Pandemic. Journal of Medical Virology. https://doi.org/10.1002/jmv.70313
Vancouver
Tachikawa J, Aizawa Y, Watanabe K, Haino K, Nishijima K, Saitoh A. Sustained Maternal Antibodies Against Parechovirus‐A3 During the Coronavirus Disease 2019 Pandemic. Journal of Medical Virology. 2025. doi:10.1002/jmv.70313
BibTeX
@article{Tachikawa2025,
author = {Tachikawa, Jun and Aizawa, Yuta and Watanabe, Kanako and Haino, Kazufumi and Nishijima, Koji and Saitoh, Akihiko},
title = {Sustained Maternal Antibodies Against Parechovirus‐A3 During the Coronavirus Disease 2019 Pandemic},
journal = {Journal of Medical Virology},
year = {2025},
doi = {10.1002/jmv.70313}
}
EUVIMED